Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is an FDA approved HER2-targeting ADC (antibody-drug conjugate). Lys-SMCC-DM1 (also known as Lys-Nε-MCC-DM1) is a drug-linker conjugate in which DM1 acts as an inhibitor of tubulin polymerization. T-DM1 is a human epidermal growth factor receptor 2 (HER2)-targeting ADC for cancer treatment.

VcMMAE (mc-vc-PAB-MMAE), a derivative of MMAE (monomethyl auristatin E) with a valine-citrulline (Vc) linker, is a drug-linker conjugate for ADC (antibody-drug-conjugate) with potent antitumor activity by utilizing the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). VcMMAE is a anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally […]

Deruxtecan (DS-8201a; DS8201a; exatecan analog; DX-8951 analog), a drug-linker conjugate for antibody-drug conjugate (ADC, Patritumab deruxtecan or U3-1402), is a novel, potent toxin and linker moiety of DS-8201.

Val-Cit-PAB-MMAE is a drug-linker conjugate used for preparing ADC (antibody-drug-conjugate) with monomethyl auristatin E (MMAE), a highly potent anti-mitotic agent as a cytotoxicin/warhead, linked via the peptide Val-Cit-PAB.

Doxorubicin-SMCC (dox-SMCC); ADR-SMCC) is a doxorubicin analog used as drug-linker conjugate for the synthesis of antibody-drug-conjugates (ADC). In Doxorubicin-SMCC, Doxorubicin is connected to a linker called SMCC (Succinimidyl-4-( N -maleimidomethyl)cyclohexane-1-carboxylate) and thus can be used to prepare doxorubicin-based bioconjugated compounds such as ADCs.

CL2-SN-38 is a cleavable linker-drug conjugate used for the synthesis of antibody drug conjugates (ADC). As a part of the antibody drug conjugate (ADC), it can conjugate with the anti-Trop-2-humanized antibody hRS7. The anti-Trop-2 hRS7-CL2A-SN-38 ADC exhibits potent and highly specific anticancer effects against a range of human solid tumor types. Reference: Humanized anti-Trop-2 IgG-SN-38 […]

CL2A-SN-38, an SN-38 (topoisomerase-I inhibitor) analogue, is a peptide-based drug linker used to synthesize antibody drug conjugates (ADC). It is composed of a potent DNA Topoisomerase I inhibitor SN-38 and a linker CL2A, which provides significant and specific anticancer effects against a panel of human solid tumors. CL2A-SN-38 is conjugated to the anti-Trop-2-humanized antibody, SN-38-anti-Trop-2 […]

SPDB-DM4 is a novel drug-linker conjugate used for the synthesis of antibody-drug-conjugate (ADC) with maytansine as the payload (DM4) which is connected to the antibody part via a SPDB linker, exhibiting potent anti-tumor activity.

SMCC-DM1 (DM1-SMCC) is DM1 (mertansine) with a reactive linker SMCC to synthesize antibody drug conjugate. DM1 (mertansine), a thiol-containing maytansinoid, is a potent microtubule-disrupting agent. DM1 is an antibody-conjugatable maytansinoid that was developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1 binds at the tips of microtubules and suppresses the […]

Vipivotide tetraxetan (also known as PSMA-617) is a novel and highly potent prostate-specific membrane antigen (PSMA) inhibitor with anticancer activity. It inhibits PSMA with a Ki of 0.37 nM. Vipivotide tetraxetan is a ligand used to make 177Lu-PSMA-617 [Pluvicto (lutetium (177Lu) vipivotide tetraxetan)], which is a radioactive molecule approved in 2022 to combat cancer. PSMA-617 […]